bromophenophos

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	89962
SCHEMBL ID	1338225
MeSH ID	M0070046

Synonyms (13)

Synonym
einecs 245-382-1
bromophenophos
4,4',6,6'-tetrabromo-2'-hydroxy(1,1'-biphenyl)-2-yl dihydrogen phosphate
2,2'-biphenyldiol, 4,4',6,6'-tetrabromo-, mono(dihydrogen phosphate)
4,4',6,6'-tetrabromo-2,2'-biphenyldiol mono(dihydrogen phosphate)
23015-40-9
u4l04459y3 ,
unii-u4l04459y3
SCHEMBL1338225
(1,1'-biphenyl)-2,2'-diol, 4,4',6,6'-tetrabromo-, mono(dihydrogen phosphate)
DTXSID90177573
4,4',6,6'-tetrabromo-2'-hydroxy[1,1'-biphenyl]-2-yl dihydrogen phosphate
Q27290677

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	10 (66.67)	18.7374
1990's	1 (6.67)	18.2507
2000's	1 (6.67)	29.6817
2010's	3 (20.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.92 (24.57)
Research Supply Index	2.89 (2.92)
Research Growth Index	4.81 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.92)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
albendazole [no description available]	2.11	1	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	1.95	1	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
tribromsalan tribromsalan: germicide; structure. tribromosalicylanilide : A salicylanilide derivative with bromo- substituents at C-3 and C-5 of the salicylate moiety and at C-4 of the anilide moiety.	2.03	1	salicylanilides
nitroxinil Nitroxinil: Proposed anthelmintic for fasciola and liver fluke infestations.	1.95	1
oxyclozanide Oxyclozanide: Anthelmintic used in grazing animals for fasciola and cestode infestations.	2.66	3
triclabendazole [no description available]	2.11	1	aromatic ether
1,1-diphenyl-2-picrylhydrazyl 1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)	2.21	1
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid: chromogen in glucose oxidase-peroxidase method for determining serum glucose; used in free radical scavenging assays; structure in first source	2.21	1
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.36	2

Condition	Relationship Strength	Studies
Diabetes Mellitus, Adult-Onset [description not available]	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.21	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.21	1
Fasciola Infection [description not available]	2.89	4
Fascioliasis Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.	2.89	4
Ovine Diseases [description not available]	2.36	2
Bovine Diseases [description not available]	1.96	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.88	4
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.37	2
Fetal Resorption The disintegration and assimilation of the dead FETUS in the UTERUS at any stage after the completion of organogenesis which, in humans, is after the 9th week of GESTATION. It does not include embryo resorption (see EMBRYO LOSS).	2.66	3
Birth Weight The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.	1.96	1
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	1.96	1

chemdatabank.com